Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezafungin Combined with Co-Trimoxazole for PCP in HIV-Infected Adults
NCT05835479Phase 2Recruiting
- Sponsor
- Mundipharma
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rezafungin in pneumocystis pneumonia (PCP) (2 arms), sponsored by Mundipharma. Primary endpoint: Therapeutic failure on Day 8. Started Nov 2023; status: recruiting.
02
Drugs
rezafungin
03
Conditions
pneumocystis pneumonia (PCP)
Beyond the preview
Go deeper on NCT05835479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835479.